The TDO–KYN–AHR signaling pathway is also activated in colorectal ovarian carcinoma, bladder carcinoma, lung carcinoma, cervix carcinoma, Ewing sarcoma, and B-cell lymphoma [15]. This evidence concerns the gene AHR and urinary bladder carcinoma.